Ranbaxy Of India Seeks To Rebuild Relations With U.S. FDA
This article was originally published in PharmAsia News
India's Ranbaxy Laboratories says in its annual report it plans to rebuild its strained relationship with U.S. FDA. Malvinder Mohan Singh, CEO and managing director of Ranbaxy, wrote in the report the company's focus is to be on resolving FDA's issues of compliance and good manufacturing practices. The company has plans to acquire FDA-approved manufacturing facilities to produce drugs once made at a pair of plants the FDA blacklisted. (Click here for more
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.